-
Vigo shares are to spin off their medical device business and list in Hong Kong.
Time of Update: 2020-10-03
On September 17th, Shandong Vigo announced that it was considering the possibility of splitting up its one-time medical device business in radiology, vascular, cardiology and oncology intervention surgery and listing independently on an accredited stock exchange.
-
East Sunshine Medicine took 9 heavy-weight varieties and 18 varieties were over-evaluated.
Time of Update: 2020-10-03
Pharmaceutical network September 18, recently, the East Sunshine pharmaceutical product line came good news, O nitrogen flat tablets were approved and treated as a review, 2 new drugs recombinant anti-VEGF humanized monoclonal antibody injection was approved clinical, 1 new drug HEC95468 clinical applications were accepted ...
-
Kyusju Tong acquires step-by-step subsidiary to undertake prescription outflow.
Time of Update: 2020-10-02
data show that Kyusju Tong, as the country's largest private pharmaceutical circulation enterprises, mainly to primary medical institutions pharmacies and private hospitals as the object, to provide drug sales and distribution services, so the company has a strong logistics and distribution capacity and terminal resources.
-
Yangtze River is showing off! 10 new class 1 drugs are eye-catching, and 63 new products are focusing on the 60 billion market...
Time of Update: 2020-10-02
Pharmaceutical network September 22nd, recently, Yangzijiang research and development pipeline happy news, 1 new drug YZJ-2440 Malay acid tablets approved clinical, 3 classes of generic drug Azishatan
-
It's going to be sunny and you're going to take the third heavy sugar pill of the year! 28.5 billion new products in the market.
Time of Update: 2020-10-01
Pharmaceutical Network September 24 recently, NMPA data show that Zhengda Tianqing Pharmaceutical Group's Kagle net tablets 4 imitation listing applications entered the "in the approval" state, if successfully approved will become the second domestic after Howson.
-
Chengdu Bett Pharmaceuticals will take the first imitation of hepatitis B god medicine.
Time of Update: 2020-09-30
Pharma Network September 25 - September 23, Chengdu Bett Pharmaceuticals to copy the four categories of reported fumarate propofol nofowe tablets into the administrative approval stage, the product developed by Gilead, as early as November 2016 was approved by the FDA for listing, 2019 global sales of $488 million.
-
Hesco is in the 700 million buck! Will Be happy to be the first review.
Time of Update: 2020-09-30
Figure 1: Hesco's Pypsypristamin tablet registration Source: NMPA's official website, Pythalpyristamin tablets for the treatment of hypertension and congestive heart failure, the product is a nonbly long-acting ACEI inhibitor, is no.
-
The National Pharmaceutical Group's share of the 2 billion-pound compound Sanofi is only 30%.
Time of Update: 2020-09-29
Figure 2: Enterprise competition pattern of Ebershatan hydrochlorochloride in 2019 Source: Minet China's public medical institutions terminal competition pattern From the enterprise pattern, the market share of the original research Sanofi (Ebersatan hydrochlorochloride tablets) fell from 40% in 2015 to about 35% in 2019, The market share of Nanjing Zhengda Tianqing Pharmaceuticals (Alliance Expansion) increased from 33% in 2015 to 34% in 2019, while that of Huahai Pharmaceutical Co., Ltd.
-
Is the sea back in blood? Half year earning 240 million 4 new products winning the bid.
Time of Update: 2020-09-29
Table 1: In recent years, Hanyu Pharmaceutical approved product sources: MED2.0 China Pharmaceutical Review Database Hanyu Pharmaceutical actively participate in the national collection, is one of Haizheng Pharmaceutical's right-hand men in the pharmaceutical field, the proportion of direct plus indirect shareholding of Hanyu Pharmaceuticals increased from 51% to 100%, not only the home-grown net profit is expected to rise significantly, but also to help the company's industrial model from "raw materials-based" to "preparation-oriented" transformation.
-
The state supports the social management of medical treatment in the United States, Maotai into the field of medical care.
Time of Update: 2020-09-28
Holdings will invest 10 billion yuan to build a new high-level non-profit international hospital in Beibei New Town, with a total of 1,500 planned beds, which is scheduled to start construction in March 2021 and be completed and operational in the first half of 2024.
-
AstraZeneta's all-out over-the-top drug sales are being monitored.
Time of Update: 2020-09-26
A foreign pharmaceutical company source revealed that the focus is because the local sales of drugs are better, included in the daily inspection; assalicon on the list of key monitoring of the injection of sodium omeprazole, introduced in China in 2007.
-
Kun Pharmaceutical Group ranks among the top 100 Chinese medicine enterprises TOP17.
Time of Update: 2020-09-25
the future, Kun Pharmaceutical Group will always focus on the health industry and slow disease management, deeply cultivate innovative research and development path, so that quality, research and development, professional efforts to reach consumers, and industry partners to create a new future of Chinese medicine.
-
More than 6.5 billion blood lipid-lowering drugs! Yellow Sea Pharmaceuticals is about to be approved.
Time of Update: 2020-09-25
In 2019, sales of Rishuvastatin at urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) reached more than 6.5 billion yuan, down 3.52% year-on-year, according to meters of intranet data.
-
A top pharmaceutical executive at a well-known pharmaceutical company has resigned.
Time of Update: 2020-09-24
on August 27, 2020, the Board of Directors of received a written resignation report from Mr. Zhu Chunlin and Mr. Yang Xiaojun, who applied to resign as a director of the Company for personal reasons, and Mr. Yang Xiaojun, who applied to resign as a director and deputy general manager of the Company for personal reasons.
-
The Sichuan company's 21 new products are eyeing the top five injections or the first reviews in the 10 billion market.
Time of Update: 2020-09-24
table 1: Chengdu Beet in the review of the consistency evaluation of supplementary application varieties in the review of 19 varieties of consistent evaluation of supplementary applications in 11 public medical institutions in China in 2019 terminal sales of more than 1 billion yuan, injection cephalosporine, hydrochloric acid right metomycin injection, injection of cephalosporine sodium, hydrochloride bromoso injection, injection of omeprazole 5 varieties sold more than 3 billion yuan per year.
-
A number of well-known pharmaceutical companies sell assets.
Time of Update: 2020-09-23
's 2020 half-year report, released recently by Haizheng Pharmaceuticals, shows that the company achieved operating income of 5.318 billion yuan and realized net profit of 240 million yuan, up 357.31% YoY, mainly due to the year-on-year decline in operating expenses due to higher gross margin on sales of the company's preparation products and higher operating efficiency.
-
Medtron announces the latest global architecture to accelerate its business orientation strategy.
Time of Update: 2020-09-23
Pharma.com, Sept. 3 (Xinhua) -- Geoff Martha, Medtron's global chief executive, announced a new restructuring of the company today. is currently the world's largest medical equipment company, headqua
-
Kangmei Pharmaceuticals lost 1.4 billion yuan in half a year, the investment in the hospital miserable!
Time of Update: 2020-09-22
semi-annual report revealed that Kangmei Health Industry Investment Co., Ltd. intends to sell guangzhou two state-owned construction land use rights and its above-ground and underground buildings and construction projects under construction for no more than 1.13 billion yuan.
-
Stone medicine breakthrough! Take 11 new products 32 varieties have been evaluated.
Time of Update: 2020-09-22
On September 4th, Shipharma Group released its interim results report, which said that in 2020 H1 achieved revenue of RMB12.59 billion, up 12.6% YoY; At present, stone medicine has 32 varieties (13 f
-
The bisceptoin pharmaceutical industry passed a consistent evaluation of the mothamine capsule.
Time of Update: 2020-09-20
Guide: This approval will enable the company's 20mg, 100mg specifications of 20mg, 100mg all through the consistent evaluation.
Company's tymoamine capsule (20mg) was approved for drug registration in December 2011 and is listed as a Class B product in the National Health Insurance Directory.
